CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer.

Building on the broad experience of its management, we have established a well-balanced portfolio of cancer therapies with our lead humanized antibody product, CT-011, in Phase II clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. An extensive portfolio of issued patents and pending patent applications worldwide protects all our products and their anticipated medical uses.

The distinctive characteristic of our products is that their efficacy peaks in the presence of an actively growing cancer, rendering them most suitable for the treatment of human malignant diseases. Our lead monoclonal antibody product, CT-011, was shown to effectively attenuate tumor growth and eliminate tumor metastases in a variety of model systems. A Phase I clinical study with CT-011 in patients with advanced-stage hematological malignancies has been completed. This study showed the antibody to be safe and well tolerated in this patient population. Furthermore, clinical responses were observed in some of the patients. Consequently, a Phase II program has been initiated including 2 sponsored studies: the first, a Phase II clinical trial in patients with diffuse large B cell lymphoma that is ongoing in the US, Israel and India . The second is a Phase II study in patients with metastatic colorectal cancer that has been started in the US with additional locations in Europe and Asia to be opened. In addition to these 2 studies, several investigator-initiated studies are about to start with the first one in patients with relapsed follicular lymphoma to be conducted at the University of Texas, MD Anderson Cancer Center.

In May 2006, the company has signed a collaboration agreement with Teva Pharmaceutical Industries for the development of CT-011 under which Teva has invested an initial $6 million in CureTech. In August 2008 this agreement has been modified with Teva agreeing to invest additional $10.5 million. The agreement stipulates further investment by Teva under certain terms and conditions. In addition, we have established several scientific collaborations that are aimed at expanding the breadth of the clinical applications of our products.  

CureTech is a privately held company with offices and laboratories located in Yavne, Israel.